# Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

> **NCT00050011** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 602 (actual)

## Conditions studied

- Breast Neoplasms
- Osteoporosis

## Interventions

- **DRUG:** Zoledronic Acid
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00050011
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 602 (ACTUAL)
- **Last updated:** 2014-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050011, "Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00050011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*